Edgewise Therapeutics Q3 net loss widens as R&D costs rise

Edgewise Therapeutics

06/11/2025 13:10

Overview

Edgewise Q3 net loss widens to $40.7 mln, with increased R&D expenses

Edgewise builds infrastructure for potential sevasemten launch in Becker

Outlook

Company expects to report GRAND CANYON data in Q4 2026

Edgewise plans CIRRUS-HCM program update in Q4 2025

Company anticipates EDG-15400 Phase 1 results in H1 2026

Result Drivers

R&D EXPENSES - Increase in R&D expenses driven by EDG-15400 Phase 1 trial initiation and CIRRUS-HCM trial patient activity

SEVASEMTEN LAUNCH PREPARATION - Co building infrastructure for potential sevasemten commercial launch in Becker

MUSCULAR DYSTROPHY TRIALS - Advancing MESA and GRAND CANYON trials in Becker muscular dystrophy

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$40.67 mln
Q3 Basic EPS
-$0.39
Q3 Operating Expenses
$46.86 mln
Q3 Operating Income
-$46.86 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Edgewise Therapeutics Inc is $38.00, about 54.3% above its November 5 closing price of $17.37

Press Release: ID:nPn1V4FnFa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)